Yes, polycythemia vera (PV) is a myeloproliferative disorder. It is one of three “classical” myeloproliferative neoplasms (MPNs) recognized by the World Health Organization, alongside essential thrombocythemia and primary myelofibrosis. All three share a common thread: the bone marrow overproduces blood cells due to a genetic mutation in the blood-forming stem cells.
What “Myeloproliferative” Actually Means
The term breaks down simply. “Myelo” refers to the bone marrow, and “proliferative” means excessive growth. In a myeloproliferative neoplasm, the bone marrow churns out too many blood cells without the usual signals telling it to stop. Each type of MPN is defined by which cell line is most affected. In essential thrombocythemia, it’s platelets. In primary myelofibrosis, scar tissue gradually replaces the marrow. In polycythemia vera, the primary problem is an overproduction of red blood cells, though white blood cells and platelets often rise too.
The WHO’s 2016 classification system groups PV with these other MPNs and uses a combination of blood counts, bone marrow biopsy findings, and genetic testing to distinguish one from another. This matters because treatment and long-term monitoring differ for each condition.
The Genetic Driver Behind PV
Nearly all cases of polycythemia vera are driven by a specific acquired mutation in a gene called JAK2. This gene normally helps regulate blood cell production. When it mutates, the signaling pathway stays permanently “on,” telling the marrow to keep making red blood cells even when the body doesn’t need them. Studies have found that roughly 95 to 97% of PV patients carry the JAK2 V617F mutation. The small remaining percentage typically have a different mutation in the same gene (JAK2 exon 12).
This is not an inherited mutation in most cases. It develops spontaneously during a person’s lifetime in a single blood-forming stem cell, which then multiplies and gradually takes over a larger share of blood production.
How PV Is Diagnosed
PV affects roughly 1.2 people per 100,000 each year. Because red blood cell counts climb slowly, many people are diagnosed through routine blood work before they ever notice symptoms. The WHO diagnostic criteria require meeting either all three major criteria or the first two major criteria plus one minor criterion.
The three major criteria are:
- Elevated hemoglobin or hematocrit: above 16.5 g/dL hemoglobin (or 49% hematocrit) in men, or above 16.0 g/dL (or 48% hematocrit) in women
- Bone marrow biopsy findings: an overly active marrow showing increased production across all three cell lines (red cells, white cells, and platelets), with characteristically varied megakaryocytes
- JAK2 mutation: positive for either JAK2 V617F or JAK2 exon 12
The minor criterion is a subnormal erythropoietin (EPO) level. EPO is the hormone your kidneys release to signal the marrow to make more red blood cells. In PV, the marrow is already overproducing on its own, so the body suppresses EPO. Over 85% of PV patients have below-normal EPO levels, with a typical median around 1.7 IU/L compared to roughly 10 IU/L in healthy individuals.
How PV Differs From Secondary Polycythemia
Not everyone with a high red blood cell count has a myeloproliferative disorder. Secondary erythrocytosis, sometimes called secondary polycythemia, raises red blood cell counts too, but for a completely different reason. In secondary cases, the body is responding to low oxygen levels caused by conditions like chronic lung disease, heart problems, or heavy smoking. The kidneys sense the oxygen deficit, release more EPO, and the marrow responds normally by producing extra red cells.
The distinction is straightforward on lab work. In PV, EPO is suppressed because the marrow doesn’t need the signal. In secondary polycythemia, EPO is normal or elevated because the body is deliberately asking for more red cells. A JAK2 mutation test and EPO level together can usually separate the two conditions quickly. This distinction determines everything about how the condition is managed going forward.
Symptoms and Daily Impact
Thickened blood from excess red blood cells causes many of PV’s hallmark symptoms: headaches, dizziness, blurred vision, and a flushed or reddish complexion. Some people experience unusual fullness after eating small meals because the spleen enlarges as it works to filter the surplus cells.
One of the most distinctive symptoms is aquagenic pruritus, an intense itching triggered by contact with water. In a study of 441 PV patients, 68% experienced this symptom. Most described it as itching, though some reported stinging or burning sensations instead. Notably, in nearly 65% of those affected, the water-triggered itching started an average of 2.9 years before PV was officially diagnosed, making it one of the earliest warning signs. Unfortunately, standard PV treatments like phlebotomy or medications that lower blood counts resolved the itching in only about 6% of patients, making it one of the most persistent quality-of-life complaints.
Blood Clots: The Primary Risk
The most serious immediate concern with PV is blood clots. Thicker blood moves more slowly and is more prone to clotting, raising the risk of both arterial events (like heart attacks and strokes) and venous events (like deep vein thrombosis and pulmonary embolism). Data from a large patient analysis found that low-dose aspirin roughly halved the incidence of both types of clots. Among patients taking aspirin, arterial thrombosis occurred in about 5% compared to 11% without it, and venous thrombosis occurred in about 4% compared to 10%.
This is why most PV management centers on keeping the hematocrit below a target threshold, typically through periodic blood draws (phlebotomy) that physically reduce the red blood cell volume. For higher-risk patients, medications that slow down marrow production are added.
Long-Term Progression
PV is a chronic condition, and most people live with it for many years. However, as a myeloproliferative neoplasm, it carries an inherent risk of evolving into more aggressive blood disorders over time. Within 15 years of diagnosis, an estimated 6 to 14% of patients develop post-PV myelofibrosis, where the marrow gradually fills with scar tissue and loses its ability to produce blood cells normally. Over the same timeframe, between 5.5 and 18.7% of patients may transform to acute myeloid leukemia, a fast-growing blood cancer that requires intensive treatment.
These risks are why ongoing monitoring is a permanent part of life with PV. Regular blood counts track whether cell production is stable or shifting, and changes in symptoms like worsening fatigue, unexplained weight loss, or a rapidly enlarging spleen can signal that the disease is entering a new phase. Early detection of progression opens up more treatment options and better outcomes.